High SMG1 expression is correlated to worse survival and is associated with lower immune infiltration in breast cancer (BRCA), Lung Adenocarcinoma (LUAD) and Pancreatic Adenocarcinoma (PAAD) patients. Here, SMG1 is linked to breast carcinoma.